Chronoscale Holdings Corp quarterly report, Q3 FY2020

Ekso Bionics Holdings, Inc. — Form 10-Q Summary

Reporting period: Quarter and nine months ended September 30, 2020. The filing identifies Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) as the registrant; this differs from the company name in the request metadata. Financial amounts below are in millions of dollars unless noted.

Business context and financial results

Ekso designs, develops, sells and rents exoskeleton devices for rehabilitation and industrial use. Its reportable segments are EksoHealth (medical) and EksoWorks (industrial).

MetricQ3 2020Q3 2019Nine months 2020Nine months 2019
Revenue$2.897$3.319$6.628$10.197
Gross profit / margin$1.813 / 63%$1.750 / 53%$3.709 / 56%$4.909 / 48%
Operating loss$2.421$3.790$10.294$13.800
Net income (loss)$2.452$0.206$(11.849)$(9.411)
Operating cash usedNot stated for quarterNot stated for quarter$7.015$14.277

Q3 net income included a $4.476 million gain from revaluing warrant liabilities, which is non-cash and sensitive to the share price; the quarter still had a $2.421 million operating loss. For the nine months, warrant revaluation produced a $1.579 million loss, contributing to the larger net loss year over year.

  • Revenue mix: Q3 EksoHealth revenue was $2.739 million and EksoWorks revenue was $0.158 million. Nine-month revenue was $6.015 million and $0.613 million, respectively.
  • Balance sheet at September 30: Cash was $14.549 million, including $2.0 million subject to the lender’s minimum-cash covenant; management estimated unrestricted cash of $12.549 million. Current assets were $21.549 million and current liabilities $5.233 million.
  • Debt and liquidity: Notes payable were $3.079 million non-current, with no current portion shown. This included a $2.0 million secured Pacific Western Bank term loan due August 2023 and a $1.086 million PPP loan, subject to possible forgiveness. The secured loan carries a cash covenant and liens on substantially all assets other than intellectual property.
  • Cash movement: Cash increased by $3.677 million over the nine months, to $14.549 million, supported by $10.704 million of net financing cash flow. Financing included $7.082 million net equity proceeds and $3.334 million from warrant exercises.

Changes versus comparable periods

  • Q3 revenue declined 13% year over year, primarily due to lower device sales amid COVID-19-related customer delays. Nine-month revenue fell 35%, with declines in both segments.
  • Gross margin improved to 63% in Q3 from 53%, and to 56% for the nine months from 48%. The company attributed improvement to higher EksoNR average selling prices, mix, lower production costs, EVO and stronger service margins.
  • Operating expenses decreased 24% in Q3 and 25% for the nine months, primarily reflecting workforce reductions and lower sales, marketing and R&D costs. A May restructuring reduced the workforce by approximately 35%; nine-month severance expense was $0.244 million.
  • Goodwill was written down by $0.189 million to zero following declining sales and margins and uncertainty around the ZeroG product line.
  • Operating cash use was 51% lower than in the first nine months of 2019, attributed to lower expenses and improved receivables collection.

Outlook, risks and unusual items

  • Management said available unrestricted cash and actions taken were expected to fund operations beyond one year from issuance of the statements. The company nevertheless reported a $195.127 million accumulated deficit and a history of operating losses and negative operating cash flows; further financing may be needed, with no assurance it will be available on acceptable terms.
  • No numerical revenue or earnings guidance was provided. Management plans continued investment in rehabilitation sales, R&D and commercialization, and industrial products, while continuing to optimize costs.
  • COVID-19 reduced demand as rehabilitation facilities deferred capital spending. The filing cites uncertainty over the pandemic’s duration and effects, customer adoption, reimbursement, competition, regulation, clinical development and financing as material risks.
  • CFIUS-related national-security concerns required termination of the China joint venture and barred Ekso from providing it technology or services. The filing says the termination was not expected to materially affect 2020 operations, but could hinder future China and broader Asian expansion.
  • An October 2020 at-the-market agreement, entered after quarter-end, permits up to $7.5 million of share sales, subject to restrictions and a minimum sale price of $6.75 per share. No shares had been sold under it through October 26, 2020.
  • Other items include $0.066 million written off in connection with the China JV, a $0.329 million warrant issuance expense, and Level 3 warrant liabilities of $4.560 million. The filing reported no pending legal proceedings expected to have a material financial effect.

Key facts for investors to verify

  • Whether revenue and customer demand recover as pandemic-related delays ease, and whether the improved gross margins persist.
  • Cash burn, covenant compliance and the impact of the secured loan and PPP forgiveness determination on liquidity.
  • Potential dilution from outstanding warrants, the October 2020 ATM facility and future financing needs.
  • Whether the company can replace China JV-related manufacturing and distribution opportunities and meet product adoption and commercialization targets.
  • The extent to which reported quarterly profit depends on volatile, non-cash warrant remeasurement rather than operating performance.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.